Catheter Precision, Inc. Shares LockeT Data in Prestigious Journal

Catheter Precision, Inc. (NYSE American: VTAK), an innovative medical device company based in the US, announced the publication of its first LockeT study in the Journal of Cardiovascular Electrophysiology. The study, titled "Feasibility, safety, and efficacy of a novel external compression vascular closure device: The LockeT Study," was released online on August 5, 2024.

This study involved 102 patients and 182 LockeT devices. It suggests LockeT is effective for hemostasis, enabling early ambulation with no major complications. Notably, 98% of patients maintained hemostasis at 2 hours, and most were discharged on the same day. The average time to ambulation was under 4 hours.

Further studies on LockeT are ongoing, with the next one expected to conclude this year, providing additional data.